论文部分内容阅读
目的在顽固性心力衰竭患者的治疗过程中应用心先安联合卡托普利治疗,回顾性分析其临床效果。方法回顾性分析我院自2015年4月~2016年4月期间所收治的62例顽固性心力衰竭患者的临床资料,利用抽签法将所有患者均分,两组患者分为研究组与对照组,每组内患者例数是31例。给予对照组患者强心利尿合剂治疗,给予研究组患者心先安联合卡托普利治疗,对比分析两组患者治疗后的组间数据。结果研究组患者的临床总有效率、症状改善时间显著性更优,差异性显著且P<0.05,统计学意义存在;研究组患者后的不良反应发生率与对照组患者进行比照研究不存在明显差异,P>0.05,统计学意义不存在。结论在顽固性心力衰竭患者的治疗过程中应用心先安联合卡托普利治疗的临床疗效较为理想。
Objective To apply Xinxian’an combined captopril in the treatment of patients with refractory heart failure and retrospectively analyze its clinical effect. Methods The clinical data of 62 patients with refractory heart failure admitted in our hospital from April 2015 to April 2016 were retrospectively analyzed. All patients were equally divided by lottery method. The two groups were divided into study group and control group , The number of patients in each group is 31 cases. Patients in control group were treated with cardiotonic diuretic combination therapy. Patients in study group were given Xinxian’an combined with captopril, and the data of two groups were compared after treatment. Results The total effective rate of clinical study and the improvement of symptoms in study group were significantly better, the difference was significant (P <0.05), there was statistical significance; there was no significant difference between the study group and the control group Difference, P> 0.05, statistical significance does not exist. Conclusion The clinical effect of Xinxian’an combined with captopril in the treatment of patients with refractory heart failure is quite satisfactory.